AAD 2024

New Developments in Dermatology

Upadacitinib: A novel treatment option for vitiligo

Presented By

Prof. Thierry Passeron, Nice University Hospital, France

Trial

Phase 2

Conference

AAD 2024

22 April, 2024 15:21

JAK1 inhibitor meets primary endpoint in prurigo nodularis

Presented By

Prof. Martin Metz, Charité University Hospital, Germany

Trial

Phase 2

Conference

AAD 2024

22 April, 2024 15:17

Botanical drug solution leads to sustained hair regrowth in paediatric alopecia

Presented By

Prof. Bianca Piraccini, University of Bologna, Italy

Trial

RAAINBOW

Conference

AAD 2024

22 April, 2024 15:14

SGLT2 inhibition: A possible mode-of-action for inflammatory skin diseases?

Presented By

Allison Holt, UMass Chan Medical School, USA

Conference

AAD 2024

22 April, 2024 15:06

Promising first results of novel topical treatment for congenital ichthyosis

Presented By

Dr Christopher Bunick, Yale School of Medicine, USA

Trial

Phase 3, ASCEND

Conference

AAD 2024

22 April, 2024 15:02

Ritlecitinib also effective in patients with total hair loss

Presented By

Dr Melissa Piliang, Cleveland Clinic, USA

Trial

Phase 3, ALLEGRO

Conference

AAD 2024

22 April, 2024 14:57

Atopic Dermatitis and Eczema in 2024

The Latest in Psoriasis

Robust long-term efficacy of bimekizumab in psoriasis

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, USA

Trial

BE BRIGHT

Conference

AAD 2024

22 April, 2024 16:09

Benefit and safety of TYK2 inhibitor ESK-001 for psoriasis in phase 2

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

Phase 2, STRIDE

Conference

AAD 2024

22 April, 2024 16:01

Durable skin clearance by IL-23 blockers due to reduction of resident memory T cells

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Trial

Phase 2, KNOCKOUT

Conference

AAD 2024

22 April, 2024 15:41

Hidradenitis Suppurativa: New Treatment Possibilities

HS: Targeting IL-1 pathway potential option after anti-TNF failure

Presented By

Prof. Falk Bechara, Ruhr-University Bochum, Germany

Trial

Phase 2

Conference

AAD 2024

22 April, 2024 16:29

BTK signalling as a novel target in hidradenitis suppurativa treatment

Presented By

Prof. Alexandra Kimball, Harvard Medical School, USA

Conference

AAD 2024

22 April, 2024 16:20

Topical ruxolitinib shows promise in milder stages of hidradenitis suppurativa

Presented By

Prof. Martina Porter, Beth Israel Deaconess Medical Center, MA, USA

Trial

Phase 2

Conference

AAD 2024

22 April, 2024 16:16

Best of the Posters

Children with atopic dermatitis may be smaller and heavier than healthy children

Presented By

Prof. Amy Paller, Northwestern University‘s Feinberg School of Medicine, USA

Trial

PEDISTAD

Conference

AAD 2024

22 April, 2024 16:54

JAK inhibitors have similar incidence rates of long-term adverse events as traditional immunomodulators

Presented By

Olivia Lamberg, University of Michigan, USA

Conference

AAD 2024

22 April, 2024 16:52

Baricitinib maintains regrowth of hair, eyebrows, and eyelashes over 3 years

Presented By

Prof. Maryanne Senna, Harvard Medical School, USA

Trial

BRAVE-AA

Conference

AAD 2024

22 April, 2024 16:43

GUIDE demonstrates: Hit hard and early in psoriasis

Presented By

Prof. Knut Schäkel, University Clinic Heidelberg, Germany

Trial

Phase 3, GUIDE

Conference

AAD 2024

22 April, 2024 16:36

Hidradenitis suppurativa treatment with secukinumab linked to low immunogenicity

Presented By

Prof. Martina Porter, Beth Israel Deaconess Medical Center, USA

Trial

Phase 3, SUNSHINE; SUNRISE

Conference

AAD 2024

22 April, 2024 16:33